A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Exclusion Criteria

• •1. Female trial participant who is pregnant or breastfeeding.
• •2. Known hypersensitivity to VS-041.
• •3. Cardiovascular disease other than HFpEF
• •4. Active intercurrent illness such as acute bacterial or viral infection.
• •5. History of illicit drug or alcohol abuse or addiction that in the opinion of the PI could affect participation.
• •6. Active chronic viral infection such as Hepatitis B, Hepatitis C or human immunodeficiency virus (HIV) at Screening.
• •7. Acute decompensated HF within 30 days of Screening
• •8. Lung disease within 12 months prior to Screening
• •9. History of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.
• •10. History of any other condition including psychiatric disorders that, in the opinion of the PI, may preclude the participant from following and completing the protocol.
• •11. Have participated within the last 6 months in a clinical study involving an investigational product.
• •12. Any other reason which, in the opinion of the PI, would prevent the participant from participating in the trial.